-
Product Insights
NewNet Present Value Model: Chimerix Inc’s ONC-201
Empower your strategies with our Net Present Value Model: Chimerix Inc's ONC-201 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Thematic Analysis
NewAutonomous Vehicles in Insurance – Thematic Intelligence
Autonomous Vehicles in Insurance Report Overview The emergence of Level 4 and 5 autonomous vehicles will alter how liability is determined in the motor insurance sector. Countries are updating traffic regulations to consider how self-driving vehicles should be legislated once driver fault is no longer a cause of incidents. Before Level 4 autonomous vehicles become mainstream, vehicles will be increasingly fitted with advanced driver assistance systems (ADAS) such as autonomous emergency braking (AEB) and automated lane-keeping systems (ALKS). Many insurers...
-
Product Insights
ONCE – Paseo de la Habana Institutional Headquarters – Madrid
Equip yourself with the essential tools needed to make informed and profitable decisions with our ONCE – Paseo de la Habana Institutional Headquarters – Madrid report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Acquire a thorough understanding of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cagrilintide in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cagrilintide in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cagrilintide in Type 2 Diabetes Drug Details: Cagrilintide is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cagrilintide in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cagrilintide in Obesity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cagrilintide in Obesity Drug Details: Cagrilintide is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval Analysis for Staphylococcal Infections
Overview How likely is it that the drugs in Staphylococcal Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Staphylococcal Infections Overview A staphylococcal infection or staph infection is an infection...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ONC-206 in Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ONC-206 in Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ONC-206 in Glioma Drug Details:ONC-206 is under development for the treatment of solid tumors...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ONC-392 in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ONC-392 in Sarcomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gotistobart in Sarcomas Drug Details: ONC-392 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval Analysis for Multiple Sclerosis
Overview How likely is it that the drugs in Multiple Sclerosis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Multiple Sclerosis Overview Multiple sclerosis (MS) is an autoimmune disease in which...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ONC-392 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ONC-392 in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gotistobart in Metastatic Melanoma Drug Details: ONC-392 is under development for...